Artivion | CRY - Selling And Administration Expenses


Artivion reported $55.75M in Selling and Administration Expenses for its fiscal quarter ending in December of 2025.





Selling And Administration Expenses Change Date
Abbott USD 4.27B 669M Sep/2026
Accuray USD 124.78M 2.54M Dec/2025
AngioDynamics USD 36.57M 3.79M Sep/2025
Artivion USD 55.75M 4.54M Dec/2025
AtriCure USD 82.56M 1.99M Jun/2026
Baxter International USD 735M 7M Jun/2026
Becton, Dickinson and Co. USD 1.26B 48M Jun/2026
Boston Scientific USD 1.8B 22M Jun/2026
Edwards Lifesciences USD 561.2M 39M Jun/2026
Inogen USD 43.77M 510K Jun/2024
Integra LifeSciences USD 161.02M 5.2M Sep/2026
J&J USD 6.25B 168M Sep/2026
Mesa Laboratories USD 27.31M 380K Sep/2024
Orthofix International USD 130.35M 11.31M Dec/2025
Pfizer USD 3.41B 496M Jun/2026
ResMed USD 290.65M 10.86M Jun/2026
Stryker USD 2.12B 32M Jun/2026
Tandem Diabetes Care USD 111.64M 3.45M Jun/2026
Teleflex USD 213.52M 12.5M Jun/2026
Terumo JPY 109.7B 5.11B Jun/2026
Trinity Biotech USD 5.78M 405K Dec/2025